Market Overview:
Anal cancer is a relatively rare type of cancer in the anal canal, and it presents with signs and symptoms of various causes, such as rectal bleeding, changes in bowel habits, and rectal pain. Anal cancer is often treatable when detected early, through the combination of radiotherapy, chemotherapy, and surgery, including other treatment procedures.
Market Size Growth Rate:
The anal cancer market was valued at USD 810.4 million in 2021 and it is projected to reach USD 1242.9 million by 2027, with a CAGR of 6.2% over the forecast period 2022-2027. Owing to an increase in the prevalence of anal cancer platforms across the globe, this is anticipated to propel the demand for the anal cancer therapeutics market. Along with increasing authorization of novel & advanced products, extensive research activities, and novel technical tools in sensor technology, the rising need for anal cancer therapeutics will further support market trends for anal cancer therapeutics through 2027.
Market Drivers:
Growing incidence rates of Squamous cell carcinoma of the anal canal (SCCA)
- Squamous cell carcinoma of the anus is common among people and more than 90% of incident cancers are associated with human papillomavirus (HPV)
- The incidence of SCCA increased by 2.7% per year with an increase in age groups 50 years and older
- In Western countries, SCC is more common than adenocarcinoma. The incidence rate of SCC is gradually increasing across the globe including in the United States, the UK, and Australia.
- Moreover, the major part of (approximately 9 out of 10 cases) anal cancers in the United States is squamous cell cancer. In addition, according to the American cancer society 2022, anticipated, about 5.4 million basal & squamous cell cancers are diagnosed each year in the US.
- According to the national library of medicine 2020, the standard treatment for rectal SCC is significant chemo radiation therapy, which results in complete regression. After completion of treatment, the survival rate from 2015 to 2019 is approximately 80%. However, nearly 30% of patients experience recurrent disease.
Market Restraints:
The high cost of treatment and stringent regulatory scenario restrain the market growth.
- The increasing cost of anal cancer therapeutics is anticipated to restrain the growth of the market expansion.
- According to the national cancer institute report-2021, the cost of anal cancer treatment in the US has increased from USD 22.3 billion in 2015 to USD 24.3 billion by 2020, an increase of 9 percent, which is a significant burden for emerging and developing countries including the US. It is one of the main significant reasons for limiting the market growth.
- Moreover, the NCI-2022 report estimates that cancer-related direct medical costs in the US were USD 183 billion in 2015 and are projected to increase to USD 246 billion by 2030, a 34% increase based only on population growth and aging.
Market Opportunities:
The majority of the significant anal cancer market players proactively working to develop potential drug products, and acquisitions to improve anal cancer treatment options.
- In October 2022, the 89 new extramural discovery science received research grants totaling USD 54.3 million from american cancer society. It will fund investigators at 65 institutions across the United States from January 1, 2023.?
- In November 2021, Pfizer Company acquired Trillium Therapeutics for approximately USD 2.22 billion, to boost its oncology portfolio with the addition of next-generation immune therapies.
Recent Developments in the Industry:
- In June 2021, Bristol Myers Squibb received European Commission approval for Opdivo plus Yervoy to treat patients of anal cancer and it has received marketing authorizes across the European region.s
- In September 2020, Incyte Company announced positive phase II clinical trials results for the efficacy and safety of its novel immunotherapy using Retifanlimab for the treatment of advanced squamous cell carcinoma
Market Segmentation:
As per the research analysis, the global anal cancer market is segmented by type of cancer into squamous cell carcinoma, carcinoma in-situ, adenocarcinoma, basal cell carcinoma, and melanoma by drug type into fluorouracil, cisplatin, carboplatin, and others (others include mitomycin, oxaliplatin, docetaxel, leucovorin, etc.) by treatment into chemotherapy, radiation therapy, immunotherapy, and surgery.
- On the bases of the cancer type, targeted therapeutics is one type of anal cancer treatment that uses drugs to selectively target cancer cells without affecting or performing normal cells of anal cancer. On the other hand, it is an effective therapy used in combination with various therapeutic methods like chemo radiation therapy. It is also known as molecularly targeted drugs and precision medicines. Significant targeted therapy can identify cancer cells, making it procedure easier for the immune system to specifically target and destroy them.
- The growing popularity of different developed novel techniques and tools in the targeted therapeutics segment is enhancing the cancer administrations including anal cancer and is anticipated to increase in demand during the coming years.
Geographical Classification:
The global anal cancer market is segmented into major countries including North America, Europe, South America, Asia Pacific, and the Middle East and Africa.
North Anal Cancer Market:
The growth of the anal cancer market in the region can be associated with the adoption of technical therapeutics such as new targeted therapeutic drugs, chemo radiation, and improvement in awareness regarding anal cancer and not only anal cancer but also various oncological disorders, increase in healthcare expenditure, and high penetration of research activities across the region.
According to the globocan report 2020, an anticipated 2,281,658 new cancer cases were diagnosed in the United States in 2020, with approximately 612,390 deaths. In addition, the most common cancers were the colon with 101,809 cases including breast 253,465, and lung 227,875, in the United States. Moreover, the majority of key players are focusing on North America through increasing FDA approval along with strategic collaborations, and more funding for extensive research and development activities is expected to boost the market in the region. For instance, In October 2022, the American cancer society approved funding for 89 new Extramural Discovery Science (EDS) research grants totaling USD 54.3 million. It will fund investigators at 65 institutions across the United States from January 1, 2023.
Europe Anal Cancer Market:
The market in Europe is estimated to be the second largest due to the increasing adoption of modern cancer therapeutic deportments, and the growing cancer disease prevalence & aging population, which is driving up demand for cancer therapeutics in clinics, hospitals, and operating rooms. In addition, colorectal cancer is the 2nd most common cancer after breast cancer in the UK, and according to the European commission-2021, there were an accounted for nearly 12.7% of all new cancer diagnoses and 12.4% of deaths in 2020.
Competitive Analysis:
However, it is expected to grow rapidly in the next couple of years with intense competition among the players and a rising number of anal cancer cases. A few key players are already being observed adopting strategies, such as collaboration for the development of therapies and drugs, which may make the market crowded with new products in the next couple of years.
Major Companies:
Novartis AG, AstraZeneca plc, Pfizer Inc., Merck & Co., Inc., Bayer AG, Bristol-Myers Squibb Company, AbbVie Inc., Hoffmann-La Roche Ltd., Johnson & Johnson Private Limited, Eli Lilly and Company, Atara Biotherapeutics Inc., Onconova Therapeutics, BioMimetix JV, LLC, Spectrum Pharmaceuticals Inc., Global BioPharma Inc., Amgen Inc., ISA Pharmaceuticals, Takeda Pharmaceutical Company Ltd., Sun Pharmaceutical Industries Ltd., Sanofi, and Others.
What we do:
We envision a world where everybody can make the best choices based on trusted information. We are here to assist you in all your market research needs our data & intelligence services to provide in-depth knowledge about new emerging drugs, treatments & diagnostics, and insights on commercial, regulatory, technological, and clinical trial landscapes. We also help in drug pipeline analysis, product commercialization strategy, R&D planning, budgeting, and more.
About Us:
Pharmanucleus is a trusted advisor in the life science & healthcare market. Our mission is to help our clients with real-time, accurate and reliable information from the industry.
For more information about the report and to request a sample copy, please visit
Contact Us:
Name: John Miller
Designation: Business Consultant
Contact no: +44 (0)20 8470 4967
Email: john.m@pharmanucleus.com
Website: http://www.pharmanucleus.com/
SOURCE PHARMA NUCLEUS